Thiazide diuretics do not potentiate cAMP response to parathyroid hormone

Area of Science:

• Endocrinology
• Pharmacology
• Nephrology

Background:

• Thiazide diuretics are known to cause hypercalcemia.
• The mechanism underlying thiazide-induced hypercalcemia is not fully understood.
• A proposed mechanism involves potentiation of the cyclic AMP (cAMP) response to parathyroid hormone (PTH).

Purpose of the Study:

• To investigate whether thiazide-induced hypercalcemia is mediated by potentiation of the cAMP response to PTH.
• To examine the effects of thiazides on phosphodiesterase and adenylate cyclase activity in bone and kidney.
• To determine if thiazides alter the cellular response to PTH in calcium-regulating tissues.

Main Methods:

• Assessed phosphodiesterase inhibition by thiazides and furosemide in bone homogenates.
• Measured basal and PTH-stimulated cAMP levels in calvaria and renal cortical slices.
• Administered thiazides to rats and measured cAMP responses in vivo.
• Evaluated effects of thiazides and furosemide on adenylate cyclase activity.
• Assessed calcemic responses to parathyroid extract and dibutyryl cAMP in thiazide-treated rats.

Main Results:

• Thiazides inhibited low-Km phosphodiesterase in bone, but furosemide was a more potent inhibitor.
• Thiazides did not alter basal or PTH-stimulated cAMP levels in vitro or in vivo.
• Thiazides and furosemide increased basal adenylate cyclase in renal cortex but did not affect PTH-stimulated activity.
• Thiazides did not affect bone adenylate cyclase, while furosemide inhibited it.
• Thiazides potentiated the calcemic response to PTH but not to dibutyryl cAMP.

Conclusions:

• Potentiation of the cAMP response to PTH does not explain thiazide-induced hypercalcemia.
• The mechanism of thiazide action on calcium metabolism likely involves pathways other than cAMP signaling modulation.
• Further research is needed to elucidate the precise mechanisms of thiazide-induced hypercalcemia.